Classify Variant
ACMG/AMP 5-class classification. 28 weighted evidence codes. Auto-suggestion from ClinVar + in-silico consensus (REVEL, CADD, AlphaMissense, SpliceAI, VEST4).
Molecular Signout Intelligence. Variants classified. Pharmacogenomics mapped. Trials matched. Every finding evidence-tiered. Free forever.
Every session evidenced · Every row ledgered · Zero PII stored
Happening right now — every post ledgered, every upvote mints COIN.
WHAT OMICSCHAT KNOWS
MOLECULAR SIGNOUT WORKFLOW
Every service governed. Every finding evidence-tiered. Every interaction ledgered. General genomics education is always free — no sign in required.
ACMG/AMP 5-class classification. 28 weighted evidence codes. Auto-suggestion from ClinVar + in-silico consensus (REVEL, CADD, AlphaMissense, SpliceAI, VEST4).
CPIC Level A drug-gene interactions. CYP2D6/tamoxifen, DPYD/5-FU, UGT1A1/irinotecan, TPMT/thiopurines, and more.
StarGEO-backed gene expression intelligence. 200K+ NCBI GEO series, 48+ validated disease signatures. NIH BD2K heritage.
5,000+ precision medicine trials from ClinicalTrials.gov matched by variant and cancer type. mCODE profile-based eligibility.
11 DRIVERS, APPROVED THERAPIES
Homologous recombination DNA repair. PARP inhibitor eligibility (olaparib, talazoparib). Platinum sensitivity context.
Exon 19 deletions + L858R — first-line osimertinib. Resistance mutations (T790M, C797S) tracked with next-line options.
Fusion drivers in NSCLC. Alectinib, brigatinib, crizotinib, entrectinib, selpercatinib — evidence-mapped by fusion partner.
Melanoma, thyroid, colorectal. Dabrafenib + trametinib combination. BRAF+EGFR for CRC (encorafenib + cetuximab).
Sotorasib, adagrasib. KRAS G12C-specific inhibitors. NSCLC + CRC approvals. Resistance mechanisms catalogued.
HER2 amplification (trastuzumab deruxtecan), NTRK fusions (larotrectinib), MSI-high (pembrolizumab pan-tumor).
WHERE OMICSCHAT GETS ITS ANSWERS
NCBI variant classification repository. Star ratings, review status, submitter agreement. ACMG evidence anchor.
Pharmacogenomics Knowledge Base. CPIC guidelines, drug-gene pairs, clinical annotations.
Catalogue of Somatic Mutations in Cancer. Sanger Institute. Tumor-specific hotspots.
MSK precision oncology knowledge base. Level 1-4 actionability tiers. FDA-approved therapy mapping.
NCBI Gene Expression Omnibus + StarGEO aggregation. 2M+ samples, 48+ validated disease signatures.
Genome Aggregation Database. Population frequency context — essential for PM2/BA1 criteria.
Genotype-Tissue Expression project. Normal tissue expression baselines. Variant-in-context interpretation.
5,000+ precision medicine trials matched by variant, cancer type, and mCODE profile.
BUILT ON STARGEO
NIH BD2K UH2CA203792 ($634K). 2M+ GEO samples aggregated into 48+ validated disease signatures. Published in Nature Scientific Data 2017. The foundation OmicsChat is built on.
Digital twins + longitudinal multi-omics. Personalized health indices. Blockchain/ledger data security. Validates OmicsChat n-of-1 reasoning architecture.
FREE FOREVER FOR PATIENTS + CLINICIANS
Variant lookup, ACMG classification, pharmacogenomics, trial matching, gene expression queries. No sign in. No credit card. Governed answers with full citation.
Enterprise features at zero cost for academic medical centers, precision medicine consortia, and community oncology networks. Request access via the CANONIC Foundation.
MAGIC 255